JAK2 and myeloproliferative neoplasm: We hypothesized that the constitutive activation of JAK2 induced by the V617F mutation itself could lead to JAK2/IRS2 binding, and that this protein association could participate in the malignant phenotype of JAK2V617F-positive MPN patients.